Kjetil Taskén

Kjetil Taskén is a full Professor at the Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, and serves as the Director of the Institute for Cancer Research, Oslo University Hospital. He leads the OUS Center for Precision Medicine in Cancer (SEPREK) since 2021 and has held multiple leadership roles in molecular medicine initiatives, including Director of the Norwegian Centre for Molecular Medicine (NCMM) and co-founder of Bioteknologisenteret.

• Current affiliations: University of Oslo | Oslo University Hospital
• Education: Dr.med. (Molecular Cell Biology) | Cand.med. | Research Leadership Course

Research interests include immunoregulation in cancer, precision oncology, cellular signal transduction in disease, and drug development targeting immune checkpoints. His work bridges translational immunology and molecular oncology, with a focus on regulatory T cell modulation for cancer therapy.

Scientific contributions span high-impact publications on regulatory T cell inhibition, precision medicine implementation, and signal pathway drug targeting. Recent articles highlight collaborations across Europe (PCM4EU, PRIME-ROSE) and Norway (IMPRESS-Norway), with methodological advances in tumor microenvironment modeling and mutation timing analysis.

• Awards: King Olav V Cancer Research Prize | Anders Jahre Medical Prize | Faculty Medal (UiO) | Norwegian Academy of Science and Letters
• Leadership: Director of NCMM | Founder of Bioteknologisenteret | Head of multiple national cancer research initiatives

Labs and teams include the Cancer Immunology Section at Oslo University Hospital and affiliations with the K. G. Jebsen Center for B-Cell Malignancies, where he co-leads research groups.